Dr. Mark David Vincent

Mark David Vincent, MB, ChB, MRCP(UK), FRCPC

Medical Oncology

London Regional Cancer Program

I received my MD from the University of Cape Town in 1976, trained in Oncology at The Royal Marsden Hospital in London, England and came to Canada in 1987.  I completed my postgraduate training in the Department of Medicine at the University of Ottawa. I am a medical oncologist at the London Regional Cancer Centre, a part of Cancer Care Ontario, where my activities include the management of lung and gastrointestinal cancer, and laboratory research into the reversal of cytotoxic drug resistance by means of gene therapy.  I am also an Associate Professor at the University of Western Ontario in the Department of Medicine, in the division of Medical oncology where I received the Award of Excellence in Teaching in 2004. My interests include the translation of basic research into the clinic, and the design and conduct of clinical trials in lung and colorectal cancer. I am also interested in toxicity minimisation/avoidance; and resistance reversal by means of genedirected therapy and small molecule chemopotentiation.

SPECIALITY QUALIFICATIONS:

Membership of the Royal College of Physicians (UK)

1990  Licentiate of the Medical Council   of Canada

                                                                     

1991  General Medical Licence, College of Physicians and Surgeons of Ontario

1991  Fellowship of the Royal College of Physicians and Surgeons of Canada

1992  Certificate of Special Competence, Medical Oncology, Royal College of Physicians and Surgeons of Canada

PUBLICATIONS:

1.  Vincent MD, Potter SG and Cooper S. Immunodepression, ascites tumour and lactate dehydrogenase virus. South African Medical Journal, 52: 924-926, 1977.

2.  Vincent MD, Clink HM, Coombes RC, Smith IE, Kandler R and Powles TJ. Aminoglutethimide (with hydrocortisone) - induced agranulocytosis in primary breast cancer. British Medical Journal, 291: 105-106, 1985.

3.  Vincent MD, Powles TJ, Skeet R, Ashley RC, Coombes RC, Gibb J, Clarke S, Thomas HL, Adcock H.  An analysis of possible prognostic features of long term and short term survivors of metastatic breast cancer. European Journal of Cancer & Clinical Oncology, 22: 1059-1065, 1986.

4.  Vincent MD, Powles TJ, Ford HT and Gazet JC. Excision of solitary lung metastases from patients with breast cancer. British Journal of Surgery, 74: 194, 1987.

5.  Vincent MD, Powles TJ, Coombes RC and McElwain TJ. Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. Cancer Chemotherapy and Pharmacology, 21: 255-260, 1988.

6.  Vincent M, Goss G, Sinoff C, Germond C, Bozek T, Helie G, Koski T, Corringham S, Corringham R. Bi-weekly vincristine, epirubicin and methylprednisolone (VEMP) in alkylator refractory multiple myeloma.  Cancer Chemotherapy and Pharmacology 34: 356-60, 1994.

7.  Vincent M, Bramwell V, Moran LA, Anderson D and the CCO PGI Systemic Treatment Disease Site Group.  Use of amifostine to  ameliorate the toxic effects of chemotherapy in the treatment of cancer.  Curr Oncol 7 (3):  149-161, 2000.

8.  Vincent M, Ho C, Tomiak A, Winquist E, Whiston F, Stitt L.  Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose.  Clin Colorectal Cancer 2 (2)L 111-118, 2002.

9.  Vincent M. Tesmilifene may enhance breast cancer chemotherapy by killing a clone of aggressive,  multi-drug resistant cells through its action on the p-glycoprotein pump.   Medical Hypotheses  66: 715-31, 2006.

CLINICAL STUDIES:

1.  Vincent MD, Dar AR et al.  A phase I study of vinblastine, cisplatin and radiation without and then with amifostine, 1995-present.  Concept originator - Dr. M.D. Vincent.

2.  Vincent MD.  ‘CarNavel’ : A Phase II Study of Carboplatin and Vinorelbine in the Treatment of Advanced Non-Small-Cell Lung Cancer.

3.  Winquist E, Vincent M. Folate/homocysteine levels in the prediction of 5FU-FA toxicity. 1999-2000. Study accrued. Data in analysis.  Concept originator - Dr. M.D. Vincent.

LABORATORY STUDIES:

1.  Vincent MD and Koropatnick J.  Antisense-mediated modification of cellular drug resistance:  Thymidylate synthase, 1992-present.

2.  Vincent MD and Ferguson P.  Modulation of toxicity of platinum drugs using a liposomal preparation of Amphotericin B, AmBisome® and Amphotericin B Methyl Ester, 1994-present. 

3.  Vincent MD, Koropatnick J. A strategy to specifically target genotoxic agents to the nuclei of cancer cells lacking expression of tumour suppression and other genes. 1998. (Inventor - M. Vincent)

Helpful Links:

 

LHSCHealth Professionals

Virtual Orientation
LRCP Orientations
For New PatientsFor New Patients Glossary of TermsGlossary of Terms Quick LinksQuick Links Contact LRCPContact LRCP Parking, Maps, DirectionsParking, Maps, Directions Upcoming EventsUpcoming Events Canadian Cancer Society Cancer Care Ontario A Cancer Care Ontario Partner
Last Updated July 10, 2007 | © 2007, LHSC, London Ontario Canada